Agile Therapeutics, Inc. (OTCPK: AGRX)
Health Care · Pharmaceuticals · US
$—
— today · — 1Y
Agile Therapeutics, Inc. (OTCPK: AGRX) operates in the Pharmaceuticals industry within the Health Care sector.
Tweenvest scores Agile Therapeutics, Inc. across four factors: quality 17/100. Its strongest factor is quality.
AGRX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $21.57M
- P/E
- —
- EPS
- -3.64
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 19
- Next earnings
- —
About Agile Therapeutics, Inc.
Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. The company is also progressing with several pipeline innovations, including variations of Twirla and other new products: AG200-15 Extended Regimen (ER): A regimen designed to limit a woman to four withdrawal bleeding occurrences annually. AG200-15 smaller patch (SmP): This iteration aims for shorter, lighter withdrawal bleeds and potentially enhanced contraceptive efficacy. AG200-15 ER SmP: A combined regimen that allows for an extended contraceptive cycle while simultaneously providing fewer, lighter annual bleeding episodes. P-Patch: A contraceptive patch containing only progestin, specifically intended for women who cannot or choose not to use estrogen. Agile Therapeutics, Inc. was founded in 1997 and is based in Princeton, New Jersey.
- ISIN
- US00847L3087
- Founded
- 1997
- Listed since
- May 23, 2014
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,235.36 | +0.14% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.50 | +0.13% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $155.85 | -0.38% |
| Roche Holding AGSWX: ROP | $371.62B | CHF370.90 | -0.78% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.18 | -1.27% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.51 | -0.21% |
Figures last refreshed Aug 18, 2026.